The DOI matches its Crossref record.
The Development of the Antitumour Benzothiazole Prodrug, Phortress, as a Clinical Candidate
Abstract
This review traces the development of a series of potent and selective antitumour benzothiazoles from the discovery of the initial lead compound, 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) in 1995 to the identification of a clinical candidate, Phortress, scheduled to enter Phase 1 trials in Q1 2004 under the auspices of Cancer Research U.K. Advances in our understanding of the mechanism of action of this unique series of agents are described and can be summarised as follows: selective uptake into sensitive cells followed by Arylhydrocarbon Receptor (AhR) binding and translocation into the nucleus, induction of the cytochrome P450 isoform (CYP) 1A1, conversion of the drug into an electrophilic reactive intermediate and formation of extensive DNA adducts resulting in cell death. Our understanding of this mechanistic scenario has played a crucial role in the drug development process, most notably in the synthesis of fluorinated DF 203 analogues to thwart deactivating oxidative metabolism (5F 203) and water-soluble prodrug design for parenteral administration. Aspects of mechanism of action studies, in vitro and in vivo screening, synthetic chemistry and pharmacokinetics are reviewed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention
Androutsopoulos, V. P., Tsatsakis, A. M., & Spandidos, D. A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-187 · Cited by 476
Mortimer, C. G., Wells, G., Crochard, J.-P., Stone, E. L., Bradshaw, T. D., Stevens, M. F. G., & Westwell, A. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050942k · Cited by 475
Self-citationRelevance of the Aryl Hydrocarbon Receptor (AhR) for Clinical Toxicology
Bradshaw, T. D., & Bell, D. R. (2009) · Clinical Toxicology · doi:10.1080/15563650903140423 · Cited by 62
Self-citation
Metadata
- Authors
- Bradshaw, T., & Westwell, A.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-04-01
- Volume
- 11
- Issue
- 8
- Pages
- 1009-1021
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2027996680
- Cited by
- 295
- References
- 0
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Development of the Antitumour Benzothiazole Prodrug, Phortress, as a Clinical Candidate. https://app.cochat.ai/papers/10.2174/0929867043455530
- The paper
- Bradshaw, T., & Westwell, A. (2004). The Development of the Antitumour Benzothiazole Prodrug, Phortress, as a Clinical Candidate. Current Medicinal Chemistry. https://doi.org/10.2174/0929867043455530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.